# EDGAR Filing Document

**Accession Number:** 0001716947
**File Stem:** 0001493152-23-001811
**Filing Date:** 2023-1
**Character Count:** 5286
**Document Hash:** 8edad9f1005bee0a4af5c0a5e7dc1976
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-001811.hdr.sgml**: 20230119

**ACCESSION NUMBER**: 0001493152-23-001811

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 52

**CONFORMED PERIOD OF REPORT**: 20230118

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230119

**DATE AS OF CHANGE**: 20230118

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ensysce Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001716947
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 822755287
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38306
- **FILM NUMBER:** 23535594

**BUSINESS ADDRESS:**
- **STREET 1:** 7946 IVANHOE AVENUE
- **STREET 2:** SUITE 201
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037
- **BUSINESS PHONE:** (858) 263-4196

**MAIL ADDRESS:**
- **STREET 1:** 7946 IVANHOE AVENUE
- **STREET 2:** SUITE 201
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Leisure Acquisition Corp.
- **DATE OF NAME CHANGE:** 20170913

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 18, 2023 (January 18, 2023)**

**Ensysce Biosciences, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38306** | **82-2755287** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification Number)** |

---

---

| | |
|:---|:---|
| **7946 Ivanhoe Avenue, Suite 201**<br> **La Jolla, California** | **92037** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(858) 263-4196**

**Registrant's telephone number, including area code**

**N/A**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, par value $0.0001 per share** | **ENSC** | **The Nasdaq Stock Market LLC** |
| **Warrants to purchase one share of Common Stock** | **ENSCW** | **OTC Pink Open Market** |

---

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01** **Other Events.**

On January 18, 2023, Ensysce Biosciences, Inc. delivered a presentation entitled "Improving Prescription Drug Safety Through Chemistry" to investors. A copy of the presentation is filed as Exhibit 99 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99 | [Investor Presentation dated January 2023](ex-99.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 18, 2023

---

| | |
|:---|:---|
| **Ensysce Biosciences, Inc.** | **Ensysce Biosciences, Inc.** |
| By: | */s/ Lynn Kirkpatrick* |
| Name: | Dr. Lynn Kirkpatrick |
| Title: | President and Chief Executive Officer |

---

## Ex-99

**Exhibit 99**

![](ex-99_001.jpg)

![](ex-99_002.jpg)

![](ex-99_003.jpg)

![](ex-99_004.jpg)

![](ex-99_005.jpg)

![](ex-99_006.jpg)

![](ex-99_007.jpg)

![](ex-99_008.jpg)

![](ex-99_009.jpg)

![](ex-99_010.jpg)

![](ex-99_011.jpg)

![](ex-99_012.jpg)

![](ex-99_013.jpg)

![](ex-99_014.jpg)

![](ex-99_015.jpg)

![](ex-99_016.jpg)

![](ex-99_017.jpg)

![](ex-99_018.jpg)

![](ex-99_019.jpg)

![](ex-99_020.jpg)

![](ex-99_021.jpg)

![](ex-99_022.jpg)

![](ex-99_023.jpg)

![](ex-99_024.jpg)

![](ex-99_025.jpg)

![](ex-99_026.jpg)

![](ex-99_027.jpg)

![](ex-99_028.jpg)

![](ex-99_029.jpg)

![](ex-99_030.jpg)

![](ex-99_031.jpg)

![](ex-99_032.jpg)

![](ex-99_033.jpg)

![](ex-99_034.jpg)

![](ex-99_035.jpg)

![](ex-99_036.jpg)

![](ex-99_037.jpg)

![](ex-99_038.jpg)